InfuSystem (NYSEAMERICAN:INFU) Upgraded at StockNews.com

StockNews.com upgraded shares of InfuSystem (NYSEAMERICAN:INFU) from a buy rating to a strong-buy rating in a research report sent to investors on Wednesday.

InfuSystem Stock Up 4.6 %

INFU opened at $8.15 on Wednesday. InfuSystem has a fifty-two week low of $7.75 and a fifty-two week high of $11.44. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.95 and a quick ratio of 1.54. The firm has a market capitalization of $173.27 million, a price-to-earnings ratio of 271.76 and a beta of 1.24.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INFU. BlackRock Inc. grew its position in shares of InfuSystem by 597.8% in the second quarter. BlackRock Inc. now owns 1,029,364 shares of the medical instruments supplier’s stock valued at $9,913,000 after purchasing an additional 881,856 shares during the period. Meros Investment Management LP grew its position in shares of InfuSystem by 51.2% in the fourth quarter. Meros Investment Management LP now owns 836,985 shares of the medical instruments supplier’s stock valued at $7,265,000 after purchasing an additional 283,591 shares during the period. State Street Corp grew its position in shares of InfuSystem by 259.5% in the second quarter. State Street Corp now owns 246,718 shares of the medical instruments supplier’s stock valued at $2,376,000 after purchasing an additional 178,087 shares during the period. Geode Capital Management LLC boosted its position in InfuSystem by 95.4% during the second quarter. Geode Capital Management LLC now owns 360,264 shares of the medical instruments supplier’s stock worth $3,469,000 after acquiring an additional 175,865 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in InfuSystem during the second quarter worth about $1,645,000. Hedge funds and other institutional investors own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.